Importantly, the therapeutic targeting of these pathways shows promise, as evidenced by rapamycin, an mTOR inhibitor widely used in clinical practice, which has demonstrated therapeutic potential in both cellular and animal models of psoriasis through its inhibition of the mTOR pathway [26,27]. This evidence concerns the gene MTOR and psoriasis.